Miller Fisher syndrome: an updated narrative review
Синдром Миллера—Фишера: обновлённый нарративный обзор
2023-08-24
SCID: 54.1/uxy38u3g
Discuss with AI
Guillain-Barré syndromeH reflexesMiller Fisher syndromeanti-GQ1b antibodiesophthalmoparesis
Figures from the paper
Abstract (AI)
Introduction: Miller Fisher syndrome (MFS) is considered a rare variant of Guillain-Barré syndrome (GBS), a group of acute-onset immune-mediated neuropathies characterized by the classic triad of ataxia, areflexia, and ophthalmoparesis. The present review aimed to provide a detailed and updated profile of all aspects of the syndrome through a collection of published articles on the subject, ranging from the initial description to recent developments related to COVID-19. Methods: We searched PubMed, Scopus, EMBASE, and Web of Science databases and gray literature, including references from the identified studies, review studies, and conference abstracts on this topic. We used all MeSH terms pertaining to "Miller Fisher syndrome," "Miller Fisher," "Fisher syndrome," and "anti-GQ1b antibody." Results: An extensive bibliography was researched and summarized in the review from an initial profile of MFS since its description to the recent accounts of diagnosis in COVID-19 patients. MFS is an immune-mediated disease with onset most frequently following infection. Anti-ganglioside GQ1b antibodies, detected in ~85% of patients, play a role in the pathogenesis of the syndrome. There are usually no abnormalities in MFS through routine neuroimaging. In rare cases, neuroimaging shows nerve root enhancement and signs of the involvement of the central nervous system. The most consistent electrophysiological findings in MFS are reduced sensory nerve action potentials and absent H reflexes. Although MFS is generally self-limited and has excellent prognosis, rare recurrent forms have been documented. Conclusion: This article gives an updated narrative review of MFS with special emphasis on clinical characteristics, neurophysiology, treatment, and prognosis of MFS patients.
Key Findings
1
Miller Fisher syndrome is a rare immune-mediated Guillain–Barré syndrome variant characterized by ataxia, areflexia, and ophthalmoparesis.
2
Miller Fisher syndrome is generally self-limited with an excellent prognosis, although rare recurrent forms and cases associated with COVID-19 have been reported.
3
Routine neuroimaging is usually normal; rare abnormalities include nerve-root enhancement and evidence of central nervous system involvement.
4
The most consistent electrophysiological findings are reduced sensory nerve action potentials and absent H-reflexes.
5
The syndrome most frequently begins after an infection, with anti-ganglioside GQ1b antibodies detected in approximately 85% of patients and implicated in pathogenesis.
Research Object
Miller Fisher syndrome (MFS)
Research Subject
The clinical characteristics, immune-mediated pathogenesis, neurophysiological and neuroimaging findings, treatment, and prognosis of MFS
Publication Details
Publication Date
2023-08-24
Journal
Publisher
ISSN
Cited by
79
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China2020
Miller Fisher syndrome and polyneuritis cranialis in COVID-192020
Clinical and immunological spectrum of the Miller Fisher syndrome2007
Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies2022
Miller Fisher syndrome1984
Miller Fisher's Syndrome2013